MedPath

Megestrol acetate

Generic Name
Megestrol acetate
Brand Names
Megace
Drug Type
Small Molecule
Chemical Formula
C24H32O4
CAS Number
595-33-5
Unique Ingredient Identifier
TJ2M0FR8ES
Background

17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.

Indication

For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.

Associated Conditions
Anorexia, Cachexia, Inoperable Carcinoma of Breast, Inoperable Endometrial Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Endometrial Carcinoma, Significant, Unexplained Weight Loss, Metastatic Endometrial carcinoma
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fed Condition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DW-ES(B) 625mg/5ml
First Posted Date
2012-05-02
Last Posted Date
2013-01-23
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
28
Registration Number
NCT01589562
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite

Phase 2
Withdrawn
Conditions
Anorexia
Interventions
First Posted Date
2011-12-29
Last Posted Date
2014-02-03
Lead Sponsor
Washington University School of Medicine
Registration Number
NCT01501396

Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fasting and Fed Condition

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2011-10-21
Last Posted Date
2014-06-25
Lead Sponsor
Asan Medical Center
Target Recruit Count
56
Registration Number
NCT01456624
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers

Phase 1
Completed
Conditions
Cachexia
Anorexia
Interventions
First Posted Date
2011-07-19
Last Posted Date
2012-07-02
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
Target Recruit Count
103
Registration Number
NCT01397214
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition

Phase 1
Conditions
Healthy Volunteers
Interventions
Drug: DW-ES(A)
First Posted Date
2011-06-28
Last Posted Date
2011-06-28
Lead Sponsor
Asan Medical Center
Target Recruit Count
15
Registration Number
NCT01383330

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Phase 3
Completed
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2010-11-09
Last Posted Date
2011-05-06
Lead Sponsor
Pfizer
Target Recruit Count
84
Registration Number
NCT01237327
Locations
🇨🇳

The 2nd Central Hospital of Tianjin, Tianjin, China

🇨🇳

Cancer Hospital, Shanghai, China

🇨🇳

The 1st Affiliated Hospital, Xi'an Jiao Tong University, Xi'an, China

and more 4 locations

Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

Phase 2
Terminated
Conditions
Anorexia
Weight Changes
Interventions
Other: clinical observation
First Posted Date
2010-09-13
Last Posted Date
2015-11-25
Lead Sponsor
Mayo Clinic
Target Recruit Count
1
Registration Number
NCT01200602
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Phase 2
Completed
Conditions
Endometrial Carcinoma
Recurrent Uterine Corpus Carcinoma
Stage IIIA Uterine Corpus Cancer
Stage IIIB Uterine Corpus Cancer
Stage IIIC1 Uterine Corpus Cancer
Stage IIIC2 Uterine Corpus Cancer
Stage IVA Uterine Corpus Cancer
Stage IVB Uterine Corpus Cancer
Interventions
Other: Laboratory Biomarker Analysis
First Posted Date
2008-08-07
Last Posted Date
2019-07-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
73
Registration Number
NCT00729586
Locations
🇺🇸

North Shore University Hospital, Manhasset, New York, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States

and more 105 locations

Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate

Not Applicable
Completed
Conditions
Adrenal Insufficiency
Interventions
First Posted Date
2007-12-17
Last Posted Date
2011-08-29
Lead Sponsor
University of Arkansas
Target Recruit Count
7
Registration Number
NCT00575029
Locations
🇺🇸

University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States

Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: placebo
First Posted Date
2007-07-27
Last Posted Date
2011-06-08
Lead Sponsor
Rottapharm Spain
Target Recruit Count
40
Registration Number
NCT00507949
Locations
🇪🇸

Neumology Service of the Hospital Universitario Dr. Peset, Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy